Immunology of Diabetes
The multidisciplinary Immunology of Diabetes Group at the IGTP is part of the Immunology Section of the Germans Trias i Pujol University Hospital (HUGTiP). It is made up of researchers, endocrinologists, pediatricians and technicians; the group works to understand more about the causes of type 1 diabetes. The research of the group is focused on translational research: Immunotherapies for the prevention and treatment of Type 1 diabetes, Pathogenic mechanisms of autoimmunity and Pediatric type 1 diabetes: tolerance, spontaneous remission and biomarkers. Their wish is to contribute to therapeutic intervention in type 1 diabetes and other autoimmune diseases. The principal investigator, Marta Vives-Pi (MSc and PhD), has been working in the field of autoimmune diseases since 1988. Since 1996 she has been the leader of several research projects, stressing the development of experimental immunotherapies. In 2000 she started the specific pathogen free Unit (SPF) at the IGTP for the study of experimental models of type 1 diabetes. Moreover, M. Vives-Pi is co-founder and scientific advisor of Ahead Therapeutics S.L. a spin-off to transfer the immunotherapy generated by the group to the clinical arena and convert know-how into treatments for autoimmune diseases such as type 1 diabetes or multiple sclerosis.
Marta Vives-Pi, (ELIMINAR)mvives(ELIMINAR)@igtp.cat, Group Leader and PI
Silvia Rodríguez Fernández,srodriguez(ELIMINAR)@igtp.cat, Predoctoral Investigator
David Perna Barrul, dperna(ELIMINAR)@igtp.cat, Predoctoral Investigator
Rosa M Ampudia, rampudia(ELIMINAR)@igtp.cat, Research Technician
Adrián Villalba, avillalba(ELIMINAR)@igtp.cat, Predoctoral Investigator
Immunotherapies for the prevention and treatment of type 1 diabetes
The line of research aims to stop the autoimmune response using innovative therapies to re-establish the cellular tolerance of the insulin-producing cells.
This line of research is funded by Instituto de Salud Carlos III and Fundació La Marató de TV3.
Pathogenic mechanisms of autoimmunity
This line of research aims to identify the mechanisms of the specific immune responsible for destruction of insulin-producing beta cells, with special atention to prenatal environmental factors.
Pediatric type 1 diabetes: tolerance, spontaneous remission and biomarkers
The aim of this line is to explore mechanisms of tolerance restablishment in children at the onset of the disease, and to define new biomarkers of remission.
This line of research is funded by DiabetesCERO.
A new dawn for type 1 diabetes: Combining a nanotherapy to halt autoimmunity with beta-cell regeneration
Efecto terapéutico de nano-liposomas en diabetes tipo 1. Determinaciones preclínicas
Terapia contra la autoinmunidad para la prevención y la curación de la diabetes tipo 1. Nanopartículas tipo liposoma que re-educan el sistema inmunológico para permitir la regeneración de las células beta
CIBERDEM IGTP Project
Spin-off Company (website pending)
Marta Vives-Pi, PhD, Principal Investigator
(+34) 93 497 86 66